Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 6/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15769569 | 1.00 | HPGD (0.47) | HPGDUSP2SMN1; SMN2RECQLEPHX1 | |
| SCHEMBL23826942 | 1.00 | HPGD (0.47) | HPGDUSP2SMN1; SMN2RECQLEPHX1 | |
| Hydrochloric Acid SCHEMBL30803165 | 0.98 | HPGD (0.46) | HPGDUSP2SMN1; SMN2RECQLEPHX1 | |
| SCHEMBL16044435 | 0.91 | HPGD (0.41) | HPGDUSP2SMN1; SMN2RECQLEPHX1 | |
| SCHEMBL24693756 | 0.91 | HPGD (0.48) | HPGDUSP2SMN1; SMN2RECQLEPHX1 | |
| SCHEMBL18838373 | 0.91 | HPGD (0.48) | HPGDUSP2SMN1; SMN2RECQLEPHX1 | |
| SCHEMBL1709273 | 0.87 | USP2 (0.49) | HPGDUSP2SMN1; SMN2GPR119KDM1A | |
| SCHEMBL29699144 | 0.86 | HPGD (0.41) | HPGDUSP2SMN1; SMN2RECQLEPHX1 | |
| SCHEMBL19332014 | 0.86 | HPGD (0.41) | HPGDUSP2SMN1; SMN2RECQLEPHX1 | |
| Hydrochloric Acid SCHEMBL29699111 | 0.84 | HPGD (0.40) | HPGDUSP2SMN1; SMN2RECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113302184-B | 1,3, 4-Oxadiazolinone compounds and medicaments | 日本新药株式会社 | 2024-11-22 | — | — | CN | disclosed |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| CN-113302184-A | 1,3, 4-oxadiazolinone compounds and drugs | 日本新药株式会社 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | PIM1, PIM3, PIM2 | HPGD 1805/4885USP2 4793/4885SMN1; SMN2 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.